Arbitration panel rules in favor of Lilly in complaint filed by Adocia
A Chicago-based arbitration panel ruled in favor of Eli Lilly and Company in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin.
New Campaign Focuses on Fighting Superbugs
Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.
Shriners Hospitals for Children Announces New Medical Device for Scoliosis Treatment Approved by FDA
A new medical device for treating scoliosis – curvature of the spine – received FDA approval, providing an alternative that both corrects the curve and maintains flexibility in the spine.
Mallinckrodt Announces Positive Top-Line Results from Pivotal Phase 3 Study of Terlipressin in Patients with HRS-1
Mallinckrodt plc announced positive top-line results from the company’s pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1 (HRS-1).
Healthline Hires Vice Presidents of Communications and Consumer Insights
Healthline Media appointed Steve Swasey as vice president of Communications and Laurie Dewan as vice president of Consumer Insights.
Jazz Pharmaceuticals Announces Acquisition of Cavion
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
Oncologie, Merck to Collaborate on Gastric Cancer Clinical Trial
Oncologie Inc. announced a clinical collaboration agreement with Merck to evaluate the combination of Oncologie’s investigational drug Bavituximab – an antibody that blocks the activity of phosphatidylserine – and Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer.
McCann Health Promotes Hilary Gentile To First Global Chief Strategy Officer
McCann Health announced Hilary Gentile’s promotion to the newly created position of Global Chief Strategy Officer.
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form
Bausch Health Companies Inc. and the company’s dermatology business Ortho Dermatologics announced that the U.S. Food and Drug Administration accepted the New Drug Application for IDP-123 (tazarotene 0.045%) Lotion, with a PDUFA action date of Dec. 22, 2019.
EVERSANA opens offices in Singapore & Mumbai
EVERSANA, a leading independent provider of global commercial services to the life science industry, announced the rapid expansion of the company’s Asia Pacific business with the addition of two new offices in Singapore and Mumbai.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!